О. Е. Данилова, Гелия Рифкатовна Гиматдинова, И. Л. Давыдкин, О. В. Терешина, В. Д. Сабанова, Г. И. Давыдкин
{"title":"血液系统恶性肿瘤患者心血管毒性评估的新方法:文献综述","authors":"О. Е. Данилова, Гелия Рифкатовна Гиматдинова, И. Л. Давыдкин, О. В. Терешина, В. Д. Сабанова, Г. И. Давыдкин","doi":"10.21320/2500-2139-2023-16-3-331-336","DOIUrl":null,"url":null,"abstract":"Since 2016, the management of cardiovascular complications has been guided by a few documents that are based on the recommendations of the European Society of Cardiology and are regularly updated. The present literature review deals with algorithms of diagnosis and correction of cardiovascular adverse events occurring on or after drug chemotherapy in patients with hematological malignancies. The aim of this paper is to analyze the literature data on optimizing the management of chemotherapy recipients, improving their quality of life as well as reducing mortality due to drug therapy-related cardiovascular complications.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Approaches to Cardiovascular Toxicity Assessment in Patients with Hematological Malignancies: A Literature Review\",\"authors\":\"О. Е. Данилова, Гелия Рифкатовна Гиматдинова, И. Л. Давыдкин, О. В. Терешина, В. Д. Сабанова, Г. И. Давыдкин\",\"doi\":\"10.21320/2500-2139-2023-16-3-331-336\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Since 2016, the management of cardiovascular complications has been guided by a few documents that are based on the recommendations of the European Society of Cardiology and are regularly updated. The present literature review deals with algorithms of diagnosis and correction of cardiovascular adverse events occurring on or after drug chemotherapy in patients with hematological malignancies. The aim of this paper is to analyze the literature data on optimizing the management of chemotherapy recipients, improving their quality of life as well as reducing mortality due to drug therapy-related cardiovascular complications.\",\"PeriodicalId\":36905,\"journal\":{\"name\":\"Klinicheskaya Onkogematologiya/Clinical Oncohematology\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klinicheskaya Onkogematologiya/Clinical Oncohematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21320/2500-2139-2023-16-3-331-336\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21320/2500-2139-2023-16-3-331-336","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
New Approaches to Cardiovascular Toxicity Assessment in Patients with Hematological Malignancies: A Literature Review
Since 2016, the management of cardiovascular complications has been guided by a few documents that are based on the recommendations of the European Society of Cardiology and are regularly updated. The present literature review deals with algorithms of diagnosis and correction of cardiovascular adverse events occurring on or after drug chemotherapy in patients with hematological malignancies. The aim of this paper is to analyze the literature data on optimizing the management of chemotherapy recipients, improving their quality of life as well as reducing mortality due to drug therapy-related cardiovascular complications.